# ICARUS-LUNG01 (NCT04940325)

> Datopotamab Deruxtecan (Dato-DXd, DS-1062a) in Advanced and/or Unresectable Non-Small Cell Lung Cancer

No report yet. It can be ordered.

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT04940325
- Phase: PHASE2
- Status: ACTIVE_NOT_RECRUITING
- Sponsor: Gustave Roussy, Cancer Campus, Grand Paris
- Conditions: Metastatic Lung Cancer; Advanced Non Small Cell Lung Cancer; Unresectable Non-small Lung Cancer
- Interventions: DS-1062a
- Enrollment: 100
- Primary outcome: Evaluation of objective response rate (ORR) based on investigator assessment

## Commentary we found

- X threads: 3

## Order

Focused, $750, price fixed at order: https://www.erudio.com/contact?report=icarus-lung01-nct04940325